Dauch Corp
No SEC Form 4 filings for $DCH in the last 30 days.
See all $DCH insider activity →Dauch Corporation (DCH) closed at $5.79 on Oct. 7, down 36% from its February high. BWS Financial reiterated a Buy rating and $17 target, 194% above the current price, citing expected EPS growth. The Dowlais acquisition doubled sales but also increased interest expenses. GM's pickup changeover is expected to cut production, impacting Dauch's volumes.
Argenx (ARGX) shares fell 8.7% in pre-market trading after discontinuing a Phase 3 study for futility. Other stocks moving lower include Caribou Biosciences (CRBU), down 3.7% after a downgrade, and several others with declines ranging from 1.8% to 7.4%.
UBS maintained a 'Buy' rating on Dauch Corp (DCH) but lowered its price target to $8.00 from $9.00. DCH's GF Value™ is $5.92, suggesting a 2.2% undervaluation. The company has a GF Score™ of 81/100, with strong growth and momentum but weaker financial strength. Eight gurus hold DCH, with mixed recent activity.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning DCH (Dauch Corp). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.
Recent DCH coverage spans earnings, financial news and market movers.
Shares likely to face continued pressure as earnings guidance remains modest and interest costs have surged.
Dauch Corp fell 4.5% in pre‑market after the price‑target cut.
Target reduction suggests modest downside pressure on DCH.
Dauch shares fell after Jefferies downgraded the company from Buy to Hold, lowering its price target from $8.25 to $7.10. The stock has declined 3.81% in the past day and 11.15% over the past year, according to market data.
Guidance lift and early cost-savings support the bull case, but financing costs and GAAP earnings weakness highlight near-term margin risk.
AlphAI scores every news story that mentions DCH with an AI model for sentiment and relevance, and aggregates insider trades from Dauch Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Dauch Corporation (DCH) closed at $5.79 on Oct. 7, down 36% from its February high. BWS Financial reiterated a Buy rating and $17 target, 194% above the current price, citing expected EPS growth. The Dowlais acquisition doubled sales but also increased interest expenses. GM's pickup changeover is expected to cut production, impacting Dauch's volumes.
2 min readArgenx (ARGX) shares fell 8.7% in pre-market trading after discontinuing a Phase 3 study for futility. Other stocks moving lower include Caribou Biosciences (CRBU), down 3.7% after a downgrade, and several others with declines ranging from 1.8% to 7.4%.
2 min readUBS maintained a 'Buy' rating on Dauch Corp (DCH) but lowered its price target to $8.00 from $9.00. DCH's GF Value™ is $5.92, suggesting a 2.2% undervaluation. The company has a GF Score™ of 81/100, with strong growth and momentum but weaker financial strength. Eight gurus hold DCH, with mixed recent activity.
1 min readDauch shares fell after Jefferies downgraded the company from Buy to Hold, lowering its price target from $8.25 to $7.10. The stock has declined 3.81% in the past day and 11.15% over the past year, according to market data.
2 min readDauch Corporation (NYSE:DCH) reported Q2 sales of about $3B and adjusted EBITDA of $389.6M (13.2% of sales), citing integration progress after its Dowlais acquisition. It raised full-year guidance: sales $10.6B-$10.8B, adjusted EBITDA $1.36B-$1.425B, adjusted FCF $260M-$325M. Net interest expense rose to $82.6M and GAAP net income fell to $1M.
6 min readDauch Corporation (DCH) held its Q2 2026 earnings call, reporting sales of $2.96B versus $1.54B prior year, boosted by $1.45B from the Dowlais acquisition. Adjusted EBITDA was $389.6M (13.2%) and adjusted free cash flow $148.4M. Full-year guidance: sales $10.6B-$10.8B and adjusted EBITDA $1.36B-$1.425B. Net leverage was 2.6x.
6 min readFactSet says about 75% of S&P 500 companies reported Q2 results, with 85% beating analyst expectations. It estimates S&P 500 earnings up 50.4% year over year and revenue up about 15%, versus 12.2% expected. The article lists multiple stocks with EPS above consensus, including ESNT, FLR, TILE, and UAA.
6 min readAmerican Axle & Manufacturing (DCH) reported Q2 adjusted EBITDA of $389.6M (13.2% of sales). It recorded $15M in quarterly synergy benefits and targets $100M+ by year-end. Cash from operations was $107.5M and adjusted free cash flow $148.4M. Full-year guidance raised: sales $10.6B-$10.8B and adjusted EBITDA $1.36B-$1.425B.
6 min readDauch Corp (DCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Dauch Reports Second Quarter 2026 Financial Results Delivers Strong Performance and Operating Cash Flow DETROIT, August 7, 2026 -- Dauch Corporation ("Dauch") (NYSE: DCH; LSE: DCH) today reported its financial results for the second quarter 2026. Second Quarter 2026 Results • Sal
6 min readBWS Financial reiterated a “buy” rating on American Axle & Manufacturing (DCH) and set a $17.00 price target, implying 192.85% upside from the prior close, according to Benzinga. Other firms issued mixed views, with RBC raising its target to $10 (“outperform”) and several downgrades to “hold” or “sell.” DCH traded at $5.80. The company reported $0.34 EPS on $2.38B revenue for the quarter.
3 min read
